GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (FRA:MIN) » Definitions » Change In Other Working Capital

Synlogic (FRA:MIN) Change In Other Working Capital : €-4.59 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Synlogic Change In Other Working Capital?

Synlogic's Change In Other Working Capital for the quarter that ended in Mar. 2024 was €-1.09 Mil. It means Synlogic's Other Working Capital declined by €1.09 Mil from Dec. 2023 to Mar. 2024 .

Synlogic's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was €-4.57 Mil. It means Synlogic's Other Working Capital declined by €4.57 Mil from Dec. 2022 to Dec. 2023 .

Synlogic Change In Other Working Capital Historical Data

The historical data trend for Synlogic's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Change In Other Working Capital Chart

Synlogic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -1.93 -2.04 -3.35 -4.57

Synlogic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.12 -0.96 -1.33 -1.22 -1.09

Synlogic Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synlogic Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Synlogic's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Synlogic (FRA:MIN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (FRA:MIN) » Definitions » Change In Other Working Capital
Comparable Companies
FBIO AXLA QSAM CNTX NRBO COCP TFFP LSTA NTRB GLTO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SYBX:USA
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Website
https://www.synlogictx.com
Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.